Philippines Launches Major Ivermectin Clinical Trial to Investigate Efficacy During Unprecedented Spike in Case in the Southeast Asian Nation

Philippines Launches Major Ivermectin Clinical Trial to Investigate Efficacy During Unprecedented Spike in Case in the Southeast Asian Nation

A senior government official in the Philippines announced the launch of a major clinical trial investigating several drugs including ivermectin, the anti-parasite medication used frequently in the tropics, in patients with COVID-19 in a quest to determine safety and efficacy. While ivermectin has grown in popularity here as an off-label treatment for COVID-19, the majority of world drug regulators and government research bodies believe the existing clinical trial data isn’t sufficient for any emergency use authorization declaration.  That’s the same here in the Philippines as the food and drug regulator in this Southeastern Asian nation cautions against use for the SARS-CoV-2 indication due to the lack of evidence. Fortunato de la Pena, the nation’s science and technology minister, declared in a presentation Monday that the ivermectin-focused clinical trial “will give us a more reliable estimate of the effects of ivermectin as an antiviral agent in mild and moderate (COVID-19) patients.”

COVID-19 Surge

With over 945,000 COVID-19 cases and more than 16,000 deaths, this country is on the edge as early on its didn’t face that great of a disruption from the pandemic—unlike count...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee